Two companies with the highest share prices on the UK stock market reassured investors on an otherwise difficult day for domestic shares.
The Cambridge-based drug company, which is the biggest stock by market value in the FTSE 100 index, held revenues steady at $10.88 billion (£8.7 billion) despite the loss of $1.46 billion (£1.2 billion) of Covid product sales in the period.
The Q1 figure beat City expectations by 3%, with Astra also above estimates at the bottom line with a core operating profit of $3.95 billion (£3.2 billion) some 11% stronger than forecasts.
Analysts at UBS said the biggest upside came in Astra’s cardiovascular, renal and metabolism franchise, with Crestor performing particularly well in emerging markets.
Respiratory was 7% ahead of expectations mainly due to asthma treatment Symbicort, while oncology was slightly above consensus as a result of strong Imfinzi sales.
In a statement ahead of the company’s AGM, chief executive Pascal Soriot pointed out that total revenue excluding Covid medicines increased 15%.
He added: “Our performance in emerging markets was particularly strong and I am impressed by the growth and pace of innovation I see in China, which underscores the competitive advantage of our leading presence in this country.”
- Lloyds Bank and NatWest among FTSE 100 mega-dividend payouts in May
- ii view: UK’s biggest company AstraZeneca doing even better than expected
- GSK exceeds expectations but Zantac overhang remains
Soriot left full-year guidance unchanged, including a forecast for earnings per share to increase by a high single-digit to low double-digit percentage.
The shares were 9,656p in October and 10,280p in early February before rallying to above 12,250p earlier this week. They fell back yesterday following results by rival GSK (LSE:GSK), but were in positive territory today in a session that consolidated the recent gains.
London Stock Exchange shares also built on their progress, having rallied to 8,056p in recent weeks as investors finally show signs of warming to December’s announcement of a strategic partnership with Microsoft (NASDAQ:MSFT).
Today’s first-quarter update backed up that momentum as LSE’s total income of £2 billion represented stronger-than-expected constant currency growth of 7.5%.
- 10 cheap FTSE 350 shares with momentum
- Insider: a big boardroom bet and massive sale at FTSE 100 hot stock
- Stockwatch: six share tips including a FTSE 100 stock to buy
This was driven by strong performances in data and analytics and post trade, whereas capital markets missed targets due to the impact of lacklustre stock market conditions.
Bank of America said one of its key takeaways from the update concerned the growth in annual subscription value to 7.6%, from 6.2% in December.
It reiterated a price target of 9,550p, still below the level seen in January 2021 of 10,000p.
The bank said: “The LSE does not look optically cheap, but we think it offers strong value for money, given its high-quality top line and operating leverage.
“This update supports our argument that it should rerate towards the US peers, given its long-term growth potential.”
These articles are provided for information purposes only. Occasionally, an opinion about whether to buy or sell a specific investment may be provided by third parties. The content is not intended to be a personal recommendation to buy or sell any financial instrument or product, or to adopt any investment strategy as it is not provided based on an assessment of your investing knowledge and experience, your financial situation or your investment objectives. The value of your investments, and the income derived from them, may go down as well as up. You may not get back all the money that you invest. The investments referred to in this article may not be suitable for all investors, and if in doubt, an investor should seek advice from a qualified investment adviser.
Full performance can be found on the company or index summary page on the interactive investor website. Simply click on the company's or index name highlighted in the article.